MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...
Drug
3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA
Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...
AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan
Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...
Abbisko Therapeutics’ Pimicotinib Earns FDA Fast-Track Status for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology firm, has announced that its colony...
BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas
Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II...
J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients
Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...
Dizal Pharmaceutical Presents Positive Trial Data for Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd, (SHA: 688192), a spin-off from AstraZeneca (AZ, NASDAQ: AZN) China...
China Medical System Gets NMPA Green Light for Phase III Vitiligo Study with Ruxolitinib Cream
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
CARsgen Therapeutics Halts Clinical Studies for Three CAR-T Therapies in the US Following FDA Request
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the US Food and Drug...
Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...
Clover Biopharmaceuticals Commences Phase I Trial for RSV Vaccine in Australia
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the successful enrollment of the first batch...
HutchMed’s Elunate-Tyvyt Combination Study for Renal Cell Carcinoma Completes Enrollment
China-based HutchMed (NASDAQ: HCM) has announced the completion of patient enrollment in its Phase II/III...
Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...
Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study
China-based Suzhou OSAI Biopharma Inc., a specialist in live biotherapeutic products (LBPs), has announced that...
Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns
Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the...
BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion
Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...